How many insider trades does FilingIQ track for APVO?

FilingIQ tracks 209 Form 4 insider transactions for APVO (Aptevo Therapeutics Inc.), covering filings from Jul 29, 2016 onwards. 24 of those were filed in the last 90 days.

Are APVO insiders net buyers or net sellers?

Across the full Form 4 history for APVO, 41 transactions (20%) were open-market purchases and 18 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does APVO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is APVO in?

Aptevo Therapeutics Inc. (APVO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $10.04M.

APVO insider trading

NasdaqCM Healthcare

Aptevo Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

209

Last 90 days

Buys / sells

20% / 9%

Market cap

$10.04M

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Company website: aptevotherapeutics.com

APVO insider activity at a glance

FilingIQ has scored 209 insider transactions for APVO since Jul 29, 2016. The most recent filing in our index is dated Aug 6, 2026.

Across the full history, 41 open-market purchases and 18 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on APVO insider trades is 61.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live APVO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 983

UNITED THERAPEUTICS Corp

NUVL 195

Nuvalent, Inc.

KYMR 193

Kymera Therapeutics, Inc.

GH 192

Guardant Health, Inc.

Hims & Hers Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for APVO?: FilingIQ tracks 209 Form 4 insider transactions for APVO (Aptevo Therapeutics Inc.), covering filings from Jul 29, 2016 onwards. 24 of those were filed in the last 90 days.
Are APVO insiders net buyers or net sellers?: Across the full Form 4 history for APVO, 41 transactions (20%) were open-market purchases and 18 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does APVO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is APVO in?: Aptevo Therapeutics Inc. (APVO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $10.04M.

Methodology & sources

Every APVO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.